A Phase 2 interventional study of Sotatercept and Sotatercept in Anemia and Kidney Failure, Chronic, sponsored by Celgene. Completed at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Anemia by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 5 of them phase 3. Anemia · Bristol-Myers Squibb.
Among the 16 studies in Anemia by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 6 in phase 2, and was the 4th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 16 studies in Anemia by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 8 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 189 across the 15 interventional studies, 190 across the 1 observational. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
1 of the studies in Anemia by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05664737Bristol-Myers SquibbA Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | 2027-07-16 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Anemia by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the optimal route of administration, dose level, and safety of intravenous and subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
Biological: Sotatercept
Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
Biological: Sotatercept
Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
Also known as: ACE-011
Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
Also known as: ACE-011
Area Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d) (14 Days)
Area Under the plasma concentration-time curve over 14-day dosing interval (AUC14) for Sotatercept., The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Area Under the Serum Concentration- Time Curve Over From Day 1 to Day 28 (AUC28d)
Area under the plasma concentration-time curve over 28-day dosing interval (AUC28d). All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Maximum Observed Serum Concentration Obtained From the First Dose (Cmax14d)
Maximum observed serum concentration (Cmax14d) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Maximum Observed Serum Concentration (Cmax28d) Obtained From the Combined First 2 Doses
Maximum observed serum concentration (Cmax28d) of sotatercept, obtained directly from the observed concentration-time data combining the profiles following the first two doses. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Time to Reach Maximum Observed Serum Concentration (Tmax)
Time to maximum serum concentration (Tmax) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
Time frame: Doses 1-2: pre- and postdose at 5 min (IV only) 4 hrs, 3, and 7 days after each dose; Doses 3-7: pre-, and postdose at 5 min after IV injection after each dose; Final dose: pre- and postdose at 5 min (IV only), 4 hrs, 3, 7, 14, 28, 56, 84, and 112 days
Estimate of Terminal Elimination Half-Life in Serum at Final Dose Only (t1/2)
Terminal elimination half-life (T1/2). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
Time frame: Predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14, 28, 56, 84, and 112 days after the final dose.
Lambda (ʎz): Apparent Terminal Rate Constant (at Final Dose Only)
Lambda, apparent terminal rate constant (final dose only). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analysis of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
Time frame: Predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14, 28, 56, 84, and 112 days after the final dose
Percentage of Participants With Mean Hemoglobin ≥ 100 g/L to ≤ 120 g/L Without Rescue Medication
The percentage of participants able to maintain a mean (Visit 14 to 17) hemoglobin concentration ≥ 100 g/L to ≤ 120 g/L without the need for rescue medication at each dose level. Mean hemoglobin value is a mean of hemoglobin concentrations from Visit 14 to Visit 17 (days 99 to 113).
Time frame: Visit 14 to Visit 17 (days 99 to 113)
Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (All Participants Regardless of Rescue)
Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].
Time frame: Baseline and Visit 14 to Visit 17 (days 99 to 113)
Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (Participants Not Rescued Prior to Day 115)
Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level for participants not rescued prior to Day 115. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].
Time frame: Baseline and Visit 14 to Visit 17 (days 99 to 113)
Number of Participants With Adverse Events (AEs)
Treatment-emergent adverse event (TEAE) was defined as an adverse event with start date on or after date of first dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participants during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A serious adverse event is defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. Severity and intensity was assessed using the following grading scale: Mild, Moderate and Severe (could be non-serious or serious).
Time frame: From date of first dose of investigational product to 112 days after the last dose or until the last study visit, whichever period was longer. The maximum duration for any IV or SC dose was 114 days. Up to approximately 226 days.
| Milestone | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 9 | 9 | 12 | 6 |
| Completed | 4 | 4 | 3 | 6 | 10 | 3 |
| Not completed | 3 | 3 | 6 | 3 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 3 | 0 | 1 | 0 |
| Withdrew: Other reasons | 1 | 0 | 3 | 1 | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 | 1 | 0 | 0 |
Area Under the plasma concentration-time curve over 14-day dosing interval (AUC14) for Sotatercept., The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
| day*ng/mL | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Area Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d) (14 Days) | 15204.31 ± 7096.55 | 11269.14 ± 1839.92 | 28647.03 ± 10332.19 | 10327.98 ± 8065.12 | 15886.83 ± 4212.12 | 21982.9 ± 5125.4 |
Area under the plasma concentration-time curve over 28-day dosing interval (AUC28d). All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
| day*ng/mL | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Area Under the Serum Concentration- Time Curve Over From Day 1 to Day 28 (AUC28d) | 38361.5 ± 8589.34 | 41500.36 ± 13647.28 | 94106.54 ± 37204.17 | 36065.09 ± 22817 | 33173.4 ± 8709.16 | 60497.8 ± 14623.13 |
Maximum observed serum concentration (Cmax14d) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
| ng/mL | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Maximum Observed Serum Concentration Obtained From the First Dose (Cmax14d) | 2567.6 ± 1093.73 | 1024.27 ± 145.8 | 4623.61 ± 1620.66 | 963.05 ± 659.65 | 3155.53 ± 1861.07 | 1993.58 ± 375.54 |
Maximum observed serum concentration (Cmax28d) of sotatercept, obtained directly from the observed concentration-time data combining the profiles following the first two doses. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
| ng/mL | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax28d) Obtained From the Combined First 2 Doses | 3557.93 ± 699.19 | 3868.83 ± 3614.89 | 8613.67 ± 3559.69 | 1967.55 ± 1128.69 | 3501.54 ± 2144.15 | 3161.6 ± 788.14 |
Time to maximum serum concentration (Tmax) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
| days | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) | 14.09 ± 14.01 | 21.01 ± 16.16 | 14.02 ± 13.99 | 18.51 ± 15.99 | 0.1688 ± 0.0035 | 21.06 ± 20.99 |
Terminal elimination half-life (T1/2). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
| days | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Estimate of Terminal Elimination Half-Life in Serum at Final Dose Only (t1/2) | 17.6 ± 4.631 | 25.87 ± 7.127 | 21.76 ± 3.941 | 21.03 ± 5.4 | 22.46 ± 5.342 | 20.39 ± 5.3 |
Lambda, apparent terminal rate constant (final dose only). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analysis of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.
| 1/day | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Lambda (ʎz): Apparent Terminal Rate Constant (at Final Dose Only) | 0.0414 ± 0.0094 | 0.0282 ± 0.0071 | 0.0328 ± 0.0063 | 0.0346 ± 0.0078 | 0.0326 ± 0.0085 | 0.0355 ± 0.0077 |
The percentage of participants able to maintain a mean (Visit 14 to 17) hemoglobin concentration ≥ 100 g/L to ≤ 120 g/L without the need for rescue medication at each dose level. Mean hemoglobin value is a mean of hemoglobin concentrations from Visit 14 to Visit 17 (days 99 to 113).
| Percentage of participants | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Percentage of Participants With Mean Hemoglobin ≥ 100 g/L to ≤ 120 g/L Without Rescue Medication | 42.9 | 42.9 | 11.1 | 33.3 | 25 | 50 |
Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].
| g/L | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (All Participants Regardless of Rescue) | -6.9 ± 11.61 | -2.7 ± 6.47 | -2.1 ± 12.23 | -0.8 ± 10.03 | -9.9 ± 9.3 | -6.4 ± 12.6 |
Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level for participants not rescued prior to Day 115. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].
| g/L | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (Participants Not Rescued Prior to Day 115) | -7 ± 6.24 | -3.6 ± 7.08 | -0.3 ± 15.2 | 0.5 ± 10.28 | -13 ± 10.07 | -1 ± 8.05 |
Treatment-emergent adverse event (TEAE) was defined as an adverse event with start date on or after date of first dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participants during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A serious adverse event is defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. Severity and intensity was assessed using the following grading scale: Mild, Moderate and Severe (could be non-serious or serious).
| Participants | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Any TEAE | 7 | 3 | 9 | 6 | 10 | 6 |
| Any Treatment-Related TEAE | 1 | 1 | 1 | 0 | 0 | 1 |
| Any Serious TEAE | 3 | 0 | 3 | 1 | 3 | 3 |
| Any Treatment-Related Serious TEAE | 0 | 0 | 0 | 0 | 0 | 0 |
| Any TEAE leading to study drug discontinuation | 0 | 0 | 3 | 0 | 1 | 0 |
| Any Severe TEAE | 0 | 0 | 2 | 0 | 1 | 2 |
| Any TEAE Leading to Death | 0 | 0 | 0 | 0 | 0 | 1 |
Collected over All-cause mortality was assessed from date of first dose to study completion (up to approximately 33 months). Serious Adverse events and other adverse events were assessed from date of first dose to 112 days after the last dose or until the last study visit, whichever period was longer, up to approximately 226 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Group 2: Sotatercept 0.2 mg/kg IV Injection | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| Group 2: Sotatercept 0.26 mg/kg SC Injection | 0/9 (0%) | 1/9 (11.1%) | 6/9 (66.7%) |
| Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | 0/12 (0%) | 3/12 (25%) | 9/12 (75%) |
| Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Event | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/7 | 0/7 | 0/9 | 0/9 | 0/12 | 1/6 |
| Mitral valve incompetenceCardiac disorders | 0/7 | 0/7 | 1/9 | 0/9 | 0/12 | 1/6 |
| Supraventricular tachycardiaCardiac disorders | 0/7 | 0/7 | 0/9 | 0/9 | 0/12 | 1/6 |
| Gastrointestinal angiodysplasia haemorrhagicGastrointestinal disorders | 0/7 | 0/7 | 0/9 | 0/9 | 0/12 | 1/6 |
| Device related infectionInfections and infestations | 0/7 | 0/7 | 0/9 | 0/9 | 0/12 | 1/6 |
| Atrial fibrillationCardiac disorders | 1/7 | 0/7 | 0/9 | 1/9 | 0/12 | 0/6 |
| Chronic gastritisGastrointestinal disorders | 1/7 | 0/7 | 0/9 | 0/9 | 0/12 | 0/6 |
| ConjunctivitisInfections and infestations | 1/7 | 0/7 | 0/9 | 0/9 | 0/12 | 0/6 |
| ParonychiaInfections and infestations | 1/7 | 0/7 | 0/9 | 0/9 | 0/12 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 1/7 | 0/7 | 0/9 | 0/9 | 0/12 | 0/6 |
| Event | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/7 | 0/7 | 1/9 | 0/9 | 1/12 | 3/6 |
| NauseaGastrointestinal disorders | 0/7 | 0/7 | 1/9 | 0/9 | 0/12 | 2/6 |
| ToothacheGastrointestinal disorders | 0/7 | 0/7 | 0/9 | 0/9 | 0/12 | 2/6 |
| InfluenzaInfections and infestations | 1/7 | 1/7 | 1/9 | 0/9 | 0/12 | 2/6 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/7 | 1/7 | 0/9 | 3/9 | 0/12 | 2/6 |
| HypertensionVascular disorders | 1/7 | 0/7 | 2/9 | 2/9 | 2/12 | 2/6 |
| Urinary tract infectionInfections and infestations | 2/7 | 0/7 | 1/9 | 0/9 | 0/12 | 0/6 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 2/7 | 2/7 | 0/9 | 1/9 | 0/12 | 0/6 |
| HaematuriaRenal and urinary disorders | 2/7 | 0/7 | 1/9 | 0/9 | 0/12 | 0/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/7 | 0/7 | 2/9 | 0/9 | 0/12 | 0/6 |
| Age, Continuous(years) | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection | Total |
|---|---|---|---|---|---|---|---|
| Mean | 59.1 ± 15.43 | 62.3 ± 13.03 | 59.4 ± 15.8 | 61.9 ± 15.43 | 61.4 ± 15.68 | 53.7 ± 15.93 | 60.0 ± 14.75 |
| Sex: Female, Male(Participants) | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 4 | 3 | 5 | 3 | 22 |
| Male | 3 | 4 | 5 | 6 | 7 | 3 | 28 |
| Race(Participants) | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection | Total |
|---|---|---|---|---|---|---|---|
| White | 4 | 5 | 6 | 8 | 11 | 6 | 40 |
| Black or African- American | 1 | 1 | 1 | 0 | 1 | 0 | 4 |
| Asian | 2 | 0 | 2 | 1 | 0 | 0 | 5 |
| American Indian/Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Ethnicity(Participants) | Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection | Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection | Group 2: Sotatercept 0.2 mg/kg IV Injection | Group 2: Sotatercept 0.26 mg/kg SC Injection | Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection | Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 7 | 6 | 8 | 9 | 12 | 6 | 48 |
Ran from Nov 2013 to primary completion in Aug 2016, 33 months.
Results were first posted in Jun 2024, 7 years 9 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 33 months is above that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept